Viatris Announces Multiple Data Presentations at ASCRS Annual Meeting

Presentations to include results from studies evaluating treatments for presbyopia, mydriasis reversal, and visual disturbances in post-refractive surgery patients.

Apr. 10, 2026 at 11:34am

Got story updates? Submit your updates here. ›

A highly detailed, translucent X-ray image of an eye, with the internal structures and components visible as glowing lines against a dark background, conceptually representing the company's focus on advancing eye care solutions.Viatris' ophthalmology research aims to shed light on the inner workings of the eye, unlocking new solutions for vision-related challenges.Today in Pittsburgh

Viatris Inc., a global healthcare company, announced that four abstracts will be presented at the upcoming American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in Washington, D.C. The presentations will cover data across various areas of ophthalmology, including results from studies evaluating treatments for presbyopia, mydriasis reversal, and visual disturbances in post-refractive surgery patients.

Why it matters

As a leading global healthcare company, Viatris' research and development efforts in ophthalmology aim to address significant unmet needs for patients, including the growing prevalence of presbyopia and visual disturbances following refractive surgery procedures. The data presentations at the ASCRS Annual Meeting showcase Viatris' commitment to advancing innovative solutions in eye care.

The details

The presentations will include full results from the VEGA-3 Phase 3 study evaluating MR-141 (phentolamine ophthalmic solution 0.75%) for presbyopia, results from a Phase 1 study of varenicline solution nasal spray in healthy Japanese adults, a post-hoc analysis of the MIRA-2 Phase 3 study evaluating the optical impact of RYZUMVI® for reversing pharmacologically-induced mydriasis, and an encore presentation of the LYNX-2 Phase 3 study evaluating MR-142 (phentolamine ophthalmic solution 0.75%) for visual disturbances in low light conditions in post-refractive surgery patients.

  • The ASCRS Annual Meeting will take place from April 10-13, 2026 in Washington, D.C.
  • The Viatris data presentations will be held on Friday, April 10 and Saturday, April 11.

The players

Viatris Inc.

A global healthcare company whose mission is to empower people worldwide to live healthier at every stage of life.

American Society of Cataract and Refractive Surgery (ASCRS)

A professional organization for ophthalmologists that hosts an annual meeting to showcase the latest research and advancements in eye care.

RYZUMVI®

A product developed by Viatris for reversing pharmacologically-induced mydriasis.

MR-141 (phentolamine ophthalmic solution 0.75%)

A Viatris product being evaluated for the treatment of presbyopia.

MR-142 (phentolamine ophthalmic solution 0.75%)

A Viatris product being evaluated for the treatment of visual disturbances in low light conditions in post-refractive surgery patients.

Got photos? Submit your photos here. ›

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

Viatris' research and development efforts in ophthalmology demonstrate the company's commitment to addressing significant unmet needs for patients, including the growing prevalence of presbyopia and visual disturbances following refractive surgery procedures.